Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?

2005-02-01

Additional Metadata
Keywords	Androgen-independent, Docetaxel, Estramustine, Prostate cancer, Survival
Persistent URL	doi.org/10.1038/ncponc0076, hdl.handle.net/1765/58654
Journal	Nature Clinical Practice Oncology
Organisation	Department of Medical Oncology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Sleijfer, S., & Stoter, G. (2005). Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?. Nature Clinical Practice Oncology, 2(2), 70–71. doi:10.1038/ncponc0076

Publication